Last updated on June 2020

Study of Elunate (Fruquintinib) in Chinese Patients With Advanced CRC

Brief description of study

A phase IV study to characterize safety of Elunate (Fruquintinib) in Chinese patients

Detailed Study Description

This is a prospective, multicenter, double-cohort, phase IV study, to evaluate safety of Elunate (Fruquintinib) in Chinese patients. There're 3 visits, including signing the ICF, 1 month after signing the ICF, 6 months after signing the ICF or 30 days after the last day of treatment. Patients who are using Elunate or plan to use Elunate within 1 week could be enrolled to this study. There're 2 cohorts for this study as below:

Cohort 1: metastatic colorectal cancer patients who are in accordance with Elunate package insert, the sample size is 2000; Cohort 2: other patients suitable for treatment with Elunate according to investigator's judgement, the sample size is 1000.

Clinical Study Identifier: NCT04005066

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.